




Strength Availability & Packaging

Asclera is available in two strengths:

- Asclera 0.5% is indicated for Spider Veins (veins ≤ 1 mm in diameter).
- Asclera 1% is indicated for Reticular Veins (veins 1 mm to 3 mm in diameter).

Each box of Asclera has 5 glass ampules, with each glass ampule containing 2 mL of Asclera.

Product Description	Product #	NDC
Asclera (Polidocanol) Injection 0.5% (10 mg per 2 mL ampule)	5000038	67850-140-05
Asclera (Polidocanol) Injection 1% (20 mg per 2 mL ampule)	5000039	67850-141-05



88% of patients treated with Asclera were satisfied after 26 weeks compared to 63% of patients treated with STS.²

INDICATION AND USAGE:

Asclera (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤ 1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity.

CONTRAINDICATIONS:

Asclera is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases.

Please consult the package insert for full prescribing information, available on request by calling Methapharm Medical Information at 1-866-701-4636, or to view and download at www.asclera.com.

To report SUSPECTED ADVERSE REACTIONS, contact Methapharm Medical Information at 1-866-701-4636, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For all other Asclera inquiries please call 1-833-766-8346 (VEIN).

REFERENCES:

1) Asclera® Full Prescribing Information. Methapharm, Inc. 2) Rabe E, Schliephake D, Otto J, Breu FX, et al. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). *Phlebology* 2010;25:124-31.



Distributed by Methapharm, Inc. Copyright © 2023 Methapharm, Inc. All rights reserved.

Asclera™ is a registered trademark of Chemische Fabrik Kreussler & Co. GmbH.




ASCLERA
(Polidocanol) Injection

THE ASCLERA DIFFERENCE

IT'S WORTH IT

BEFORE TREATMENT



**Telangiectasias /
spider veins**
≤ 1 mm in diameter

**Small varicose /
reticular veins**
1 to 3 mm in diameter

What is Asclera®?¹

Asclera (polidocanol) injection is indicated for use in the lower extremity to sclerose:

- Uncomplicated spider veins (varicose veins ≤1 mm in diameter).
- Uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter).

Note: Asclera is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases

Administration¹

Use 0.1 mL to 0.3 mL for each injection with a maximum volume of 10 mL per session.

Solution strength depends on the size and extent of the veins. Extensive varicosities may require multiple treatment sessions separated by 1-2 weeks.

POST TREATMENT CARE

In Clinic¹

After the needle has been removed and the injection site has been covered, apply compression in the form of a stocking or bandage.

Walk for 15 to 20 minutes immediately after the procedure and daily for the next few days.

Compression¹

Maintain compression for 2 to 3 days after treatment for spider veins and 5 to 7 days for reticular veins. Continue for 2 to 3 weeks during the daytime.

Compression stockings or support hose should be thigh or knee high depending upon the area treated in order to provide adequate coverage.

Long Term¹

For two to three days following treatment, avoid heavy exercise, sunbathing, long plane flights, and hot baths or sauna.


Small intravaricose thrombi (trapped blood or retained coagulum) that develop may be removed by microthrombectomy (puncture aspiration or extraction).

AFTER TREATMENT



Improvement 18 weeks after last treatment.*
**Individual results may vary.*

EASI Study: Asclera vs STS²



A prospective, randomized, multicenter study of 316 patients that received sclerotherapy with either 0.5% or 1% Asclera (POL), or 1% STS.

Superior Safety Performance

